Sotrovimab
- Generic Name
- Sotrovimab
- Brand Names
- Xevudy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2423014-07-5
- Unique Ingredient Identifier
- 1MTK0BPN8V
- Background
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.
Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.
- Indication
In Europe, sotrovimab is indicated for the treatment of COVID-19 in patients ≥12 years old and weighing ≥40kg who do not require supplemental oxygen and are at high risk of progressing to severe disease.
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19)
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.